Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xianjun Yu

Showing results (231-240 of 421) with videos related to

Pageof 43
Sort By:
Frontiers in Oncology|March 15, 2021
Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic LandscapeHe Xu, Jie Hua, Qingcai Meng, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|July 9, 2019
Management of solid pseudopapillary neoplasms of pancreas: A single center experience of 243 consecutive patientsMengqi Liu, Jiang Liu, Qiangsheng Hu, et al.
Oncology Letters|April 30, 2017
Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumorsGuopei Luo, Chen Liu, He Cheng, et al.
Drug Design, Development and Therapy|March 10, 2015
Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancerKaizhou Jin, Guopei Luo, Zhiwen Xiao, et al.
Translational Oncology|May 14, 2023
Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxia in PDACMingwei Dong, Rong Tang, Wei Wang, et al.
International Journal of Surgery (London, England)|July 18, 2025
Main pancreatic duct exposure, repair or reconstruction During minimally invasive pancreatic enucleation long-term metabolic outcome From a prospective cohort study (CSPAC-MIEN-1)Zheng Li, Yihua Shi, Qifeng Zhuo, et al.
Cancer Immunology, Immunotherapy : CII|October 23, 2025
Assessment of tertiary lymphoid structures via <sup>18</sup>F-FDG PET/CT scan in patients with pancreatic adenocarcinomaYu Yan, Xuan Zou, Xuan Lin, et al.
Signal Transduction and Targeted Therapy|December 20, 2025
A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinomaRan Xue, Miaoyan Wei, Jiajia Yuan, et al.
Endocrine|January 17, 2023
Recent progress of experimental model in pancreatic neuroendocrine tumors: drawbacks and challengesYan Wang, Fei Wang, Yi Qin, et al.
Cellular and Molecular Life Sciences : CMLS|June 16, 2021
Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinomaAbudureyimu Tuerhong, Jin Xu, Si Shi, et al.
Pageof 43

Showing results (231-240 of 421) with videos related to

Sort By:
Pageof 43
Frontiers in Oncology|March 15, 2021
Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic LandscapeHe Xu, Jie Hua, Qingcai Meng, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|July 9, 2019
Management of solid pseudopapillary neoplasms of pancreas: A single center experience of 243 consecutive patientsMengqi Liu, Jiang Liu, Qiangsheng Hu, et al.
Oncology Letters|April 30, 2017
Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumorsGuopei Luo, Chen Liu, He Cheng, et al.
Drug Design, Development and Therapy|March 10, 2015
Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancerKaizhou Jin, Guopei Luo, Zhiwen Xiao, et al.
Translational Oncology|May 14, 2023
Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxia in PDACMingwei Dong, Rong Tang, Wei Wang, et al.
International Journal of Surgery (London, England)|July 18, 2025
Main pancreatic duct exposure, repair or reconstruction During minimally invasive pancreatic enucleation long-term metabolic outcome From a prospective cohort study (CSPAC-MIEN-1)Zheng Li, Yihua Shi, Qifeng Zhuo, et al.
Cancer Immunology, Immunotherapy : CII|October 23, 2025
Assessment of tertiary lymphoid structures via <sup>18</sup>F-FDG PET/CT scan in patients with pancreatic adenocarcinomaYu Yan, Xuan Zou, Xuan Lin, et al.
Signal Transduction and Targeted Therapy|December 20, 2025
A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinomaRan Xue, Miaoyan Wei, Jiajia Yuan, et al.
Endocrine|January 17, 2023
Recent progress of experimental model in pancreatic neuroendocrine tumors: drawbacks and challengesYan Wang, Fei Wang, Yi Qin, et al.
Cellular and Molecular Life Sciences : CMLS|June 16, 2021
Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinomaAbudureyimu Tuerhong, Jin Xu, Si Shi, et al.
Pageof 43